112 related articles for article (PubMed ID: 32896486)
1. Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer.
Kim CW; Kim TW; Lee JL; Park IJ; Yoon YS; Lim SB; Yu CS; Kim JC
Clin Colorectal Cancer; 2020 Dec; 19(4):e157-e163. PubMed ID: 32896486
[TBL] [Abstract][Full Text] [Related]
2. Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study.
van den Berg I; van de Weerd S; Roodhart JML; Vink GR; van den Braak RRJC; Jimenez CR; Elias SG; van Vliet D; Koelink M; Hong E; van Grevenstein WMU; van Oijen MGH; Beets-Tan RGH; van Krieken JHJM; IJzermans JNM; Medema JP; Koopman M;
BMC Cancer; 2020 Aug; 20(1):776. PubMed ID: 32811457
[TBL] [Abstract][Full Text] [Related]
3. Elevated postoperative carcinoembryonic antigen guides adjuvant chemotherapy for stage II colon cancer: a multicentre cohort retrospective study.
Pu H; Yang W; Liu M; Pang X; Chen Y; Xiong Q
Sci Rep; 2024 Mar; 14(1):6889. PubMed ID: 38519578
[TBL] [Abstract][Full Text] [Related]
4. Survival paradox between stage IIB/C and stage IIIA colon cancer: is it time to revise the American Joint Committee on Cancer TNM system?
Chu QD; Li T; Hsieh MC; Yi Y; Gibbs JF; Sahawneh J; Sang W; Gallagher J; Wu XC
Surg Endosc; 2024 May; 38(5):2857-2870. PubMed ID: 38575828
[TBL] [Abstract][Full Text] [Related]
5. The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
Liao L; Tang J; Hong Z; Jiang W; Li Y; Kong L; Han K; Hou Z; Zhang C; Zhou C; Zhang L; Sui Q; Xiao B; Mei W; Yu J; Yang W; Pan Z; Ding PR
BMC Cancer; 2024 Feb; 24(1):164. PubMed ID: 38302968
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Tie J; Cohen JD; Lahouel K; Lo SN; Wang Y; Kosmider S; Wong R; Shapiro J; Lee M; Harris S; Khattak A; Burge M; Harris M; Lynam J; Nott L; Day F; Hayes T; McLachlan SA; Lee B; Ptak J; Silliman N; Dobbyn L; Popoli M; Hruban R; Lennon AM; Papadopoulos N; Kinzler KW; Vogelstein B; Tomasetti C; Gibbs P;
N Engl J Med; 2022 Jun; 386(24):2261-2272. PubMed ID: 35657320
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Implications of Endoscopic Obstruction in Patients with Pathological Stage II Colon Cancers: a Single-Center Retrospective Cohort Study.
Mo TW; Zhang ZJ; Shi YQ; Xiang HD; Chen YL; Chen ZX; Hu JC; He XW
J Gastrointest Surg; 2023 Jan; 27(1):141-151. PubMed ID: 36352061
[TBL] [Abstract][Full Text] [Related]
9. A new prognostic and predictive tool for shared decision making in stage III colon cancer.
Sobrero AF; Puccini A; Shi Q; Grothey A; Andrè T; Shields AF; Souglakos I; Yoshino T; Iveson T; Ceppi M; Bruzzi P
Eur J Cancer; 2020 Oct; 138():182-188. PubMed ID: 32892120
[TBL] [Abstract][Full Text] [Related]
10. Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).
Cheng E; Ou FS; Ma C; Spiegelman D; Zhang S; Zhou X; Bainter TM; Saltz LB; Niedzwiecki D; Mayer RJ; Whittom R; Hantel A; Benson A; Atienza D; Messino M; Kindler H; Giovannucci EL; Van Blarigan EL; Brown JC; Ng K; Gross CP; Meyerhardt JA; Fuchs CS
J Clin Oncol; 2022 Mar; 40(7):740-751. PubMed ID: 34995084
[TBL] [Abstract][Full Text] [Related]
11. Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial).
Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Matsui S; Teramukai S; Murotani K; Ajioka Y; Shimazaki H; Maeda A; Takuma K; Yoshida T; Kambara T; Matsuda K; Takagane A; Tomita N; Sugihara K;
Am J Surg Pathol; 2020 Dec; 44(12):1685-1698. PubMed ID: 32868525
[TBL] [Abstract][Full Text] [Related]
12. Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer.
Okuyama T; Sameshima S; Takeshita E; Mitsui T; Noro T; Ono Y; Noie T; Ban S; Oya M
BMC Cancer; 2020 Sep; 20(1):842. PubMed ID: 32883261
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of CEA Improves Risk Stratification in Stage II Colon Cancer.
Spindler BA; Bergquist JR; Thiels CA; Habermann EB; Kelley SR; Larson DW; Mathis KL
J Gastrointest Surg; 2017 May; 21(5):770-777. PubMed ID: 28290141
[TBL] [Abstract][Full Text] [Related]
14. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.
Srivastava G; Renfro LA; Behrens RJ; Lopatin M; Chao C; Soori GS; Dakhil SR; Mowat RB; Kuebler JP; Kim G; Mazurczak M; Lee M; Alberts SR
Oncologist; 2014 May; 19(5):492-7. PubMed ID: 24710310
[TBL] [Abstract][Full Text] [Related]
15. Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system.
Chen Y; Shankaran V; Hahn EE; Haupt EC; Bansal A
J Manag Care Spec Pharm; 2023 Jun; 29(6):635-646. PubMed ID: 37276035
[No Abstract] [Full Text] [Related]
16. Impact of perineural invasion on survival in node negative colon cancer.
Mirkin KA; Hollenbeak CS; Mohamed A; Jia Y; El-Deiry WS; Messaris E
Cancer Biol Ther; 2017 Sep; 18(9):740-745. PubMed ID: 28475454
[TBL] [Abstract][Full Text] [Related]
17. Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands.
van Steenbergen LN; Lemmens VEPP; Rutten HJT; Wymenga ANM; Nortier JWR; Janssen-Heijnen MLG
Ann Oncol; 2012 Nov; 23(11):2805-2811. PubMed ID: 22562836
[TBL] [Abstract][Full Text] [Related]
18. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial.
Tsikitis VL; Malireddy K; Green EA; Christensen B; Whelan R; Hyder J; Marcello P; Larach S; Lauter D; Sargent DJ; Nelson H
J Clin Oncol; 2009 Aug; 27(22):3671-6. PubMed ID: 19564531
[TBL] [Abstract][Full Text] [Related]
19. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor-stroma ratio in colon cancer.
Polack M; Smit MA; van Pelt GW; Roodvoets AGH; Meershoek-Klein Kranenbarg E; Putter H; Gelderblom H; Crobach ASLP; Terpstra V; Petrushevska G; Gašljević G; Kjær-Frifeldt S; de Cuba EMV; Bulkmans NWJ; Vink GR; Al Dieri R; Tollenaar RAEM; van Krieken JHJM; Mesker WE;
ESMO Open; 2024 Apr; 9(4):102988. PubMed ID: 38613913
[TBL] [Abstract][Full Text] [Related]
20. Peri-operative bowel perforation in early stage colon cancer is associated with an adverse oncological outcome.
Belt EJ; Stockmann HB; Abis GS; de Boer JM; de Lange-de Klerk ES; van Egmond M; Meijer GA; Oosterling SJ
J Gastrointest Surg; 2012 Dec; 16(12):2260-6. PubMed ID: 23093449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
